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otrial fibrillation (AF) is a rapidly evolving epidemic rep-
esenting a multifactorial, dynamic disorder with different
nderlying substrates and serious health consequences (1).
growing body of evidence indicates that, apart from the
riggers, AF development and perpetuation depends on the
lectrical and structural remodeling of the atria (2,3).
urrently, the role of the renin-angiotensin-aldosterone
ystem in AF is under intensive investigation (4), whereas
uch of the current interest regarding pharmacologic ther-
py has shifted to nonchannel-blocking drugs with pleio-
ropic properties including agents interfering in the renin-
ngiotensin-aldosterone system (2,4,5).
See page 758
Specifically, the role of aldosterone in AF has not been
ell studied. Indirect evidence from hypertensive patients
ith primary aldosteronism indicates increased prevalence
f AF (6). Three previously published laboratory studies,
hich examined the role of aldosterone and its blockade on
trial remodeling, focused on heart failure experimental
odels (7–9). They showed that aldosterone blockade
educes atrial fibrosis (7,9) and suppresses AF (8,9). On the
linical level, the existent data is sparse and conflicting.
oette et al. (10) reported that aldosterone levels are
levated in patients with persistent AF, whereas restoration
f sinus rhythm lowers serum aldosterone. However, an-
ther study showed no significant association between AF
nd aldosterone levels when use of diuretics was included in
he multivariate model, suggesting that the excessive acti-
ation of the renin-angiotensin-aldosterone axis by volume
epletion may be the primary mechanism of aldosterone
ncrease (11). Moreover, a recent genetic analysis showed
hat a specific polymorphism related to increased aldoste-
one synthase activity pre-disposes to AF in patients with
eart failure (12). Interestingly, a small randomized con-
rolled study in heart failure patients has demonstrated that
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.g
From the Department of Cardiology, University of Ioannina School of Medicine,
oannina, Greece.pironolactone treatment reduces the risk for AF/atrial
utter (13).
In this issue of the Journal, Tsai et al. (14), using
tate-of-the-art methodology, provide important new infor-
ation on this subject combining clinical and experimental
ata. The investigators showed that aldosterone is not
ynthesized locally in the atrial tissue and its principal effects
n the atria depend on the expression of mineralocorticoid
eceptors (MRs), which mediate its genomic effects. Al-
hough there was no difference in the atrial aldosterone
evel, the patients with AF, compared with sinus rhythm
atients, had increased MR expression. In a second set of
xperiments using an atrial cell line it was shown that rapid
epolarization induces increased MR expression through
alcium-dependent mechanisms enhancing aldosterone re-
ponsiveness. Of note, aldosterone increased intracellular
alcium load and induced electrical remodeling through a
enomic (MR-dependent) pathway without the contribu-
ion of oxidative stress. Specifically, aldosterone increased
-type calcium current, decreased rapidly activating delayed
ectifier potassium current, and had no effect on L-type
alcium current. These changes were attenuated by the
oadministration of spironolactone. It should also be noted
hat aldosterone increased intracellular oxidative stress by a
ongenomic pathway (nicotinamide adenine dinucleotide
hosphate oxidase-dependent). As the investigators cor-
ectly point out, the aforementioned pathways indicate a
ositive feedback vicious cycle (14).
Undoubtedly, these results represent a step forward to the
nderstanding of signaling pathways in atrial remodeling
nd further reinforce the potential value of MR antagonists
n AF. They also provide evidence for effective modulation
f calcium overload by MR blockers, given that calcium-
hannel blockers have failed to control AF and atrial
lectrical remodeling in the clinical setting. However, it
hould be acknowledged that the remodeling process is very
omplex and several aspects remain obscure. As with any
ood study, the questions and the unclear points outnumber
he answers.
First, the present results cannot be easily extrapolated in
ther populations despite the fact that an additional small
roup of patients without significant valvular disease was
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Aldosterone Signaling in AF February 23, 2010:771–3xamined. The main population of the study consisted of
ubjects with severe mitral or aortic regurgitation subjected
o cardiac surgery. Even though the ejection fraction does
ot reliably reflect the systolic function especially in the case
f severe mitral regurgitation, the patients of both groups
ad normal left ventricular ejection fractions. Unfortunately,
ther indexes of systolic and diastolic function were not
eported. In fact, it is not known whether aldosterone
ignaling is different in subjects with underlying substrates
uch as ischemic cardiomyopathy, dilated cardiomyopathy,
ypertension, and so on. It is also unclear whether aldoste-
one signaling changes according to the extent of atrial
emodeling. Although the AF patients of the study had
ermanent AF with a mean duration of 8.3 years and larger
tria than sinus rhythm patients did, the investigators did
ot find any important differences in indexes of fibrosis and
xtracellular matrix, and the in vitro experiments showed no
ignificant effect of aldosterone. Despite some inconsistent
esults regarding atrial fibrosis, aldosterone is considered a
ey component of structural remodeling especially at the
entricular level (15). Taking into account that aldosterone
s implicated in the ventricular remodeling, it is reasonable
o assume that the resulting ventricular systolic and diastolic
ysfunction and the associated elevation of diastolic pres-
ures promote AF due to increased atrial stretch. Atrial
tretch can induce both structural and electrical remodeling
mechanoelectrical phenomenon). These latter mechanisms
ay be operative in the population of the present study
ecause valvular regurgitations cause a volume overload.
The investigators showed that aldosterone increases in-
racellular oxidative stress by a nongenomic pathway and,
herefore, this cannot be attenuated by MR blocking. They
lso reported that oxidative stress does not mediate
ldosterone-induced electrical remodeling in the cellular
odel. However, a growing body of evidence suggests that
xidative stress is implicated in both electrical and structural
trial remodeling (16–18). In a recent review, Gao and
udley (18) illuminate the central role of redox-sensitive
uclear factor kappa-B in the regulation of ion channels,
ranscription factors, or splicing factors implicated in atrial
emodeling. Although Tsai et al. (14) showed in their
ellular model that MR blockade is not able to modulate
ntracellular oxidative stress, one cannot ignore that a
omplex interplay exists among angiotensin, aldosterone,
nd oxidative signaling pathways. In this context, Johar et
l. (19) demonstrated that aldosterone mediates angiotensin
I-induced cardiac fibrosis via nicotinamide adenine dinu-
leotide phosphate oxidase whereas spironolactone inhibits
xidative stress as well as the profibrotic effect of angiotensin
I. Also, current data from human atrial tissues supports the
otion that oxidative stress is implicated in electrical remod-
ling and is associated with the attenuation of L-type
alcium current (20). It is therefore tempting to speculate
hat a combined intervention targeting the nuclear factor
appa-B signaling, oxidative and inflammatory pathways,
nd the renin-angiotensin-aldosterone axis would be ofpecial merit in this setting. It has also been suggested that
he aldosterone-induced oxidative damage depends on the
re-existing redox status (21), whereas MR activation
aused by change in the redox status is accompanied by
nflammation (22). Notably, the present study does not
rovide data on serum or atrial tissue markers of oxidative
tress and inflammation.
Calcium overload and calcium-handling abnormalities
eem to have an important role in AF pathophysiology (23).
he aldosterone-dependent electrical remodeling mediated
y calcium overload is a novel, worthwhile finding. How-
ver, the investigators studied the effect of rapid electrical
timulation only in the cellular model. In the clinical setting,
atients with permanent AF such as those included in the
rst part of the study have prominent structural remodeling.
lso, it is known that the rapid calcium influx after the
nitiation of rapid atrial depolarization is attenuated over
ime due to adaptive mechanisms (2,23). The intracellular
alcium handling over long periods of sustained AF prob-
bly is different and abnormalities in calcium release and
euptake from the sarcoplasmic reticulum may have the
rimary role (23). Bukowska et al. (24) recently demon-
trated that tachycardia-induced calcium overload of human
trial tissue slices induces oxidative stress, mitochondrial
ysfunction, and activation of the nuclear factor kappa-B
ignaling pathway. Moreover, calcium overload has been
mplicated in myocyte loss and apoptosis, in the contractile
emodeling/systolic dysfunction, and in the genesis of after-
epolarizations and the associated triggered activity. Given
hat the increased firing activity of ectopic foci, mainly in
he pulmonary veins, is critical for the initiation of AF, it
ould be very interesting to examine the aldosterone sig-
aling in this setting.
In conclusion, the present findings should be further
nvestigated in different settings, including various forms
f AF, distinct underlying substrates, and both for
rimary and secondary prevention of AF (25). Further-
ore, the role of MR blockade in different types and
tages of atrial remodeling remains to be determined. It
ould also be interesting to test the effect of eplerenone
ecause it is considered more selective for the MR and
ppears to have more nongenomic effects than spirono-
actone does. The journey to identify specific targets and
pecific time points for implementing novel prevention
nd management strategies in AF continues.
eprint requests and correspondence: Dr. Panagiotis Koran-
zopoulos, Department of Cardiology, University of Ioannina
chool of Medicine, Stavrou Niarchou-1, 45221 Ioannina,
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